Drugs / IMA203CD8
last change May 2019 re-read 2 minutes ago

IMA203CD8

Developed for
refractory malignant neoplasm
Investigated by
Immatics US, Inc.

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03686124 May 2019 → Dec 2028 expected refractory malignant neoplasm Immatics US, Inc. Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IMA203CD8 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03686124